ORAMED PHARMACEUTICALS INC.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
ORMP$4.00+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Equity
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
U.S. Dollars in thousands
| Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | $ | capital | deficit | equity | interests | equity | |
| In thousands | |||||||
| BALANCE AS OF DECEMBER 31, 2024 | 39,920 | $480 | $322,401 | $(176,616) | $146,265 | $(918) | $145,347 |
| CHANGES DURING THE NINE MONTH PERIOD ENDED SEPTEMBER 30, 2025: | |||||||
| STOCK-BASED COMPENSATION | 1,248 | 14 | 3,694 | - | 3,708 | - | 3,708 |
| REPURCHASE AND RETIREMENT OF COMMON STOCK | (329) | (4) | (728) | - | (732) | - | (732) |
| NET INCOME (LOSS) | - | - | - | 54,041 | 54,041 | (34) | 54,007 |
| BALANCE AS OF SEPTEMBER 30, 2025 | 40,839 | $490 | $325,367 | $(122,575) | $203,282 | $(952) | $202,330 |
| Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | $ | capital | deficit | equity | interests | equity | |
| In thousands | |||||||
| BALANCE AS OF DECEMBER 31, 2023 | 40,339 | $485 | $320,892 | $(157,556) | $163,821 | $(928) | $162,893 |
| CHANGES DURING THE NINE MONTH PERIOD ENDED SEPTEMBER 30, 2024: | |||||||
| STOCK-BASED COMPENSATION | 410 | 5 | 2,777 | - | 2,782 | - | 2,782 |
| STOCK-BASED COMPENSATION OF SUBSIDIARY | - | - | - | - | - | 42 | 42 |
| REPURCHASE AND RETIREMENT OF COMMON STOCK | (539) | (6) | (1,285) | (1,291) | (1,291) | ||
| NET LOSS | - | - | - | (8,871) | (8,871) | (33) | (8,904) |
| BALANCE AS OF SEPTEMBER 30, 2024 | $40,210 | $484 | $322,384 | $(166,427) | $156,441 | $(919) | $155,522 |
| Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | $ | capital | deficit | equity | interests | equity | |
| In thousands | |||||||
| BALANCE AS OF JUNE 30, 2025 | 40,845 | $491 | $325,008 | $(170,970) | $154,529 | $(946) | $153,583 |
| CHANGES DURING THE THREE MONTH PERIOD ENDED SEPTEMBER 30, 2025: | |||||||
| STOCK-BASED COMPENSATION | 159 | 1 | 718 | - | 719 | - | 719 |
| REPURCHASE AND RETIREMENT OF COMMON STOCK | (165) | (2) | (359) | - | (361) | - | (361) |
| NET INCOME (LOSS) | - | - | - | 48,395 | 48,395 | (6) | 48,389 |
| BALANCE AS OF SEPTEMBER 30, 2025 | 40,839 | $490 | $325,367 | $(122,575) | $203,282 | $(952) | $202,330 |
| Common Stock · Additional paid-in · Accumulated · Total stockholders’ · Non- controlling · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares | $ | capital | deficit | equity | interests | equity | |
| In thousands | |||||||
| BALANCE AS OF JUNE 30, 2024 | 40,629 | $488 | $323,385 | $(146,808) | $177,065 | $(911) | $176,154 |
| CHANGES DURING THE THREE MONTH PERIOD ENDED SEPTEMBER 30, 2024: | |||||||
| STOCK-BASED COMPENSATION | 120 | 2 | 284 | - | 286 | - | 286 |
| STOCK-BASED COMPENSATION OF SUBSIDIARY | - | - | - | - | - | 15 | 15 |
| REPURCHASE AND RETIREMENT OF COMMON STOCK | (539) | (6) | (1,285) | (1,291) | (1,291) | ||
| NET LOSS | - | - | - | (19,619) | (19,619) | (23) | (19,642) |
| BALANCE AS OF SEPTEMBER 30, 2024 | 40,210 | $484 | $322,384 | $(166,427) | $156,441 | $(919) | $155,522 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.